In November 2019, Daiichi Sankyo filed a Declaratory Judgment action in the District Court of Delaware against Seagen in response to communications from Seagen claiming certain intellectual ...

On December 23, 2020, Daiichi Sankyo filed a petition with the U.S. Patent Office for post-grant review contesting the patentability of certain claims within the ’039 patent. About Daiichi Sankyo ...

TOKYO and SAN DIEGO, Sept. 28, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) (TSE:4568) and Ambit Biosciences (AMBI), jointly announced today that they have ...

Daiichi Sankyo now expects Enhertu could reach JPY 195.2 billion ($1.31 billion) sales in fiscal year 2022, a big increase from the previous JPY 128.4 billion forecast.

Merck agreed to pay Daiichi Sankyo $5.5 billion for the rights to jointly develop and commercialize three of its candidate cancer drugs, in a deal that could be worth up to $22 billion depending ...

TOKYO, January 31, 2025--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer ...

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.

An AstraZeneca and Daiichi Sankyo cancer drug achieved one of the main goals of a Phase 3 study in non-small cell lung cancer. But patient deaths were also reported in the study, and the companies ...

An AstraZeneca and Daiichi Sankyo cancer drug achieved one of the main goals of a Phase 3 study in non-small cell lung cancer. But patient deaths were also reported in the study, and the companies ...

Daiichi rose 14% Friday after Merck agreed to pay $4 billion upfront and as much as $22 billion to develop and market the drug candidates. One them is them slated to seek US approval by March 2024 ...

Daiichi Sankyo raised $3.2 billion through the sale, according to Bloomberg News, which cited an unnamed “person with knowledge of the matter” because the amount raised is considered private ...

Daiichi Sankyo's environmental, social, and governance risks are included in our valuation. Like any other pharmaceutical company, access to basic services (tied to drug pricing) is an ESG risk ...